In critically ill patients, inflammatory proteins called cytokines disrupt how the body converts thyroid hormone into its active form, causing less active T3 and more inactive reverse T3, which may slow metabolism.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
An RCT could prove that blocking specific cytokines (e.g., IL-6) prevents the decline in T3 and rise in rT3 in critically ill patients.
A double-blind RCT of 150 adult ICU patients with early sepsis, randomized to receive intravenous tocilizumab (IL-6 receptor blocker) or placebo, measuring serum T3, FT4, rT3, and D1/D3 activity in serial blood samples over 72 hours as primary endpoints.
A prospective cohort could confirm that rising IL-6 levels precede and predict the decline in T3 and rise in rT3 in ICU patients.
A prospective cohort study measuring serial serum IL-6, TNF-α, T3, FT4, and rT3 every 12 hours for 7 days in 300 ICU patients, using time-series analysis to determine if cytokine peaks precede T3 decline and rT3 rise.
A case-control study could compare deiodinase enzyme activity in liver tissue from critically ill patients who died versus those who survived.
A case-control study comparing postmortem liver tissue from 50 critically ill patients who died with NTIS to 50 matched controls who died of non-critical illness, measuring D1 and D3 mRNA and protein expression via qPCR and immunohistochemistry.
A cross-sectional study could correlate serum cytokine levels with deiodinase activity markers in a single ICU population.
A cross-sectional study measuring serum IL-6, TNF-α, and rT3/T3 ratio in 200 ICU patients within 24 hours of admission, and correlating these with serum markers of D1 activity (T3/rT3 ratio).
An expert opinion can synthesize existing mechanistic data but cannot prove biological causation.
A narrative review summarizing human and animal studies on cytokine effects on deiodinases, as presented in this document.